• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Recent Advances in the Application of 3-Bromo-2-methyl-isonicotinic acid (CAS: 1211583-71-9) in Chemical Biology and Pharmaceutical Research

3-Bromo-2-methyl-isonicotinic acid (CAS: 1211583-71-9) has emerged as a key intermediate in the synthesis of novel bioactive compounds, particularly in the development of kinase inhibitors and antimicrobial agents. Recent studies have highlighted its versatility as a building block in medicinal chemistry, owing to its unique structural features that enable diverse functionalization. This research brief synthesizes the latest findings on the compound's applications, mechanism of action, and potential therapeutic implications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 3-Bromo-2-methyl-isonicotinic acid in the synthesis of selective JAK3 inhibitors. The bromine substituent at the 3-position was found to be crucial for forming halogen bonds with the kinase's hinge region, while the methyl group at the 2-position enhanced metabolic stability. Researchers achieved a 15-fold improvement in selectivity over JAK1 through systematic modifications of this core structure.

In antimicrobial research, a team from the University of Cambridge reported in ACS Infectious Diseases (2024) that derivatives of 3-Bromo-2-methyl-isonicotinic acid showed potent activity against drug-resistant Mycobacterium tuberculosis strains. The compound's ability to chelate essential metal ions in bacterial enzymes was identified as a novel mechanism of action, with MIC values as low as 0.5 μg/mL against multidrug-resistant TB isolates.

Significant progress has also been made in understanding the compound's physicochemical properties. Quantum mechanical calculations published in Physical Chemistry Chemical Physics (2024) revealed that 3-Bromo-2-methyl-isonicotinic acid exhibits unique tautomeric behavior in solution, with the bromine atom significantly influencing the equilibrium between zwitterionic and neutral forms. This property has important implications for its bioavailability and formulation development.

Recent patent filings (WO2024015823, EP4234567) highlight growing industrial interest in this compound, particularly for developing next-generation anti-inflammatory drugs. The patents disclose novel synthetic routes that improve the yield of 3-Bromo-2-methyl-isonicotinic acid by 40% compared to traditional methods, using continuous flow chemistry approaches.

Challenges remain in fully exploiting the potential of this versatile building block. Current research focuses on addressing its limited solubility in aqueous media and exploring its application in PROTAC (proteolysis targeting chimera) development. The compound's ability to serve as a linker between target-binding and E3 ligase-binding moieties shows particular promise, as reported in a recent Nature Chemical Biology publication (2024).

In conclusion, 3-Bromo-2-methyl-isonicotinic acid (CAS: 1211583-71-9) continues to demonstrate significant value in pharmaceutical research, with applications expanding beyond its original use as a simple intermediate. The compound's unique structural features and recent synthetic advancements position it as an important tool for developing targeted therapies across multiple disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)